000303021 001__ 303021
000303021 005__ 20250722114136.0
000303021 0247_ $$2doi$$a10.1007/s00277-025-06491-y
000303021 0247_ $$2pmid$$apmid:40663111
000303021 0247_ $$2ISSN$$a0939-5555
000303021 0247_ $$2ISSN$$a0006-5242
000303021 0247_ $$2ISSN$$a1432-0584
000303021 037__ $$aDKFZ-2025-01468
000303021 041__ $$aEnglish
000303021 082__ $$a610
000303021 1001_ $$aErnst, Jana$$b0
000303021 245__ $$aSuccessful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease.
000303021 260__ $$aNew York$$bSpringer$$c2025
000303021 3367_ $$2DRIVER$$aarticle
000303021 3367_ $$2DataCite$$aOutput Types/Journal article
000303021 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753097302_5172
000303021 3367_ $$2BibTeX$$aARTICLE
000303021 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303021 3367_ $$00$$2EndNote$$aJournal Article
000303021 500__ $$aepub
000303021 520__ $$aAcute graft-versus-host disease (aGVHD) as complication after allogeneic hematopoetic stem cell transplantation (allo-HSCT) occurs in up to 70% of patients. The survival prognosis depends on the severity of GVHD and response to first-line therapy. In patients who are refractory to both, steroids and ruxolitinib, an unmet medical need exists, especially in severe gastrointestinal forms of aGVHD. We report the case of a 12-year-old male patient who developed severe gastrointestinal aGVHD after allo-HSCT for the treatment of high-risk acute myeloid leukemia. The grade IV aGVHD of the intestine showed no improvement under triple immunosuppression with corticosteroids, cyclosporine A and ruxolitinib. After receiving four weekly infusions of human allogeneic mesenchymal stromal cells DRK-BaWü-He-FFM (MSC-FFM), intestinal inflammation finally improved, as reflected by ameliorated symptoms, normalized intestinal wall thickness (ultrasonography) and decreasing calprotectin levels. Intestinal mucosal healing was further supported by a strict, formula-based modular diet. The present case supports efficacy and safety of MSC-FFM in combination with modular nutrition in complicated courses of aGVHD of the intestine refractory to multiple lines of therapy and introduces intestinal wall thickness and calprotectin levels as valuable markers of disease activity.
000303021 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303021 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303021 650_7 $$2Other$$aAcute graft-versus-host disease
000303021 650_7 $$2Other$$aCalprotectin
000303021 650_7 $$2Other$$aHematopoietic stem cell transplantation
000303021 650_7 $$2Other$$aIntestinal wall thickness
000303021 650_7 $$2Other$$aMSC-FFM
000303021 650_7 $$2Other$$aMesenchymal stromal cells
000303021 7001_ $$aReinsch, Steffen$$b1
000303021 7001_ $$aMentzel, Hans-Joachim$$b2
000303021 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b3$$udkfz
000303021 7001_ $$aGruhn, Bernd$$b4
000303021 773__ $$0PERI:(DE-600)1458429-3$$a10.1007/s00277-025-06491-y$$pnn$$tAnnals of hematology$$vnn$$x0939-5555$$y2025
000303021 909CO $$ooai:inrepo02.dkfz.de:303021$$pVDB
000303021 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303021 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303021 9141_ $$y2025
000303021 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000303021 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-27$$wger
000303021 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN HEMATOL : 2022$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000303021 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-27
000303021 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000303021 980__ $$ajournal
000303021 980__ $$aVDB
000303021 980__ $$aI:(DE-He78)B310-20160331
000303021 980__ $$aUNRESTRICTED